Protocol paper: a multi-center, double-blinded, randomized, 6-month, placebo-controlled study followed by 12-month open label extension to evaluate the safety and efficacy of Saracatinib in Fibrodysplasia Ossificans Progressiva (STOPFOP)

被引：0
作者：
Bernard J. Smilde
Clemens Stockklausner
Richard Keen
Andrew Whittaker
Alex N. Bullock
Annette von Delft
Natasja M. van Schoor
Paul B. Yu
E. Marelise W. Eekhoff
机构：
[1] Amsterdam UMC location Vrije Universiteit Amsterdam,Department of Internal Medicine Section Endocrinology
[2] Amsterdam Movement Sciences,Tissue Function and Regeneration
[3] Klinikum Garmisch-Partenkirchen,Department of Paediatrics
[4] Royal National Orthopaedic Hospital,Department of Rheumatology
[5] BioPharmaceuticals R&D,Emerging Innovations Unit, Discovery Sciences
[6] AstraZeneca,Centre for Medicines Discovery, Nuffield Department of Medicine
[7] University of Oxford,Oxford Biomedical Research Centre, National Institute for Health Research
[8] University of Oxford,Epidemiology and Data Science
[9] Amsterdam UMC location Vrije Universiteit Amsterdam,Aging and Later Life
[10] Amsterdam Public Health,Cardiovascular Research Center
[11] Massachusetts General Hospital,undefined
来源：
BMC Musculoskeletal Disorders | / 23卷
关键词：
Fibrodysplasia Ossificans Progressiva; Saracatinib; AZD0530; Clinical trial; Drug repurposing; Drug repositioning;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 196 条
  • [1] Nguengang Wakap S(2020)Estimating cumulative point prevalence of rare diseases: Analysis of the Orphanet database Eur J Hum Genet 28 165-173
  • [2] Lambert DM(2019)The burden of rare diseases Am J Med Genet A 179 885-892
  • [3] Olry A(2009)Rare diseases clinical research N: Clinical research for rare disease: Opportunities, challenges, and solutions Mol Genet Metab 96 20-26
  • [4] Rodwell C(2017)Prevalence of fibrodysplasia ossificans progressiva (FOP) in France: An estimate based on a record linkage of two national databases Orphanet J Rare Dis 12 123-146
  • [5] Gueydan C(2021)Prevalence of fibrodysplasia ossificans progressiva (FOP) in the United States: Estimate from three treatment centers and a patient organization Orphanet J Rare Dis 16 350-656
  • [6] Lanneau V(2018)[18F]NaF PET/CT scan as an early marker of heterotopic ossification in fibrodysplasia ossificans progressiva Bone 109 143-691
  • [7] Murphy D(2016)The natural history of flare-ups in Fibrodysplasia Ossificans Progressiva (FOP): A comprehensive global assessment J Bone Miner Res 31 650-390
  • [8] Le Cam Y(2010)Early mortality and cardiorespiratory failure in patients with fibrodysplasia ossificans progressiva J Bone Joint Surg Am 92 686-22553
  • [9] Rath A(2009)Classic and atypical fibrodysplasia ossificans progressiva (FOP) phenotypes are caused by mutations in the bone morphogenetic protein (BMP) type I receptor ACVR1 Hum Mutat 30 379-522
  • [10] Ferreira CR(2015)ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A Sci Transl Med 7 303ra137-167
12345678910